CSBio CSBio

X
[{"orgOrder":0,"company":"Ubiquigent","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Ubiquigent Continues Drug Discovery Collaboration With Bristol Myers Squibb","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery Platform","country":"UNITED KINGDOM","productType":"Undisclosed","productStatus":"Undisclosed","date":"June 2020","url1":"","url2":"","graph1":"Undisclosed","graph2":"Ubiquigent"},{"orgOrder":0,"company":"Horizon Discovery Group","sponsor":"TrueBinding","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Horizon Discovery Licenses CHOSOURCE Platform to Truebinding for Development and Commercialization of Multiple Biotherapeutics","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery Platform","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","productStatus":"Undisclosed","date":"July 2020","url1":"","url2":"","graph1":"Cell and Gene therapy","graph2":"Horizon Discovery Group"},{"orgOrder":0,"company":"Oxford Biotherapeutics","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Boehringer Ingelheim and Oxford BioTherapeutics Expand Collaboration to Discover Novel Selective Tumor Targets as First Bispecific Antibody Advanced into the Clinic","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery Platform","country":"UNITED KINGDOM","productType":"Large molecule","productStatus":"Undisclosed","date":"October 2020","url1":"","url2":"","graph1":"Large molecule","graph2":"Oxford Biotherapeutics"},{"orgOrder":0,"company":"Artios Pharma Limited","sponsor":"Merck Group","pharmaFlowCategory":"D","amount":"$6,910.0 million","upfrontCash":"$30.0 million","newsHeadline":"Merck KGaA and Artios Pharma Announce a Global Strategic Collaboration on Novel DNA Damage Response Targets in Oncology","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery Platform","country":"UNITED KINGDOM","productType":"Large molecule","productStatus":"Undisclosed","date":"December 2020","url1":"","url2":"","graph1":"Large molecule","graph2":"Artios Pharma Limited"},{"orgOrder":0,"company":"Theolytics","sponsor":"Epidarex Capital","pharmaFlowCategory":"D","amount":"$6.8 million","upfrontCash":"Undisclosed","newsHeadline":"Theolytics Raises $6.8 million Series A Round Co-Led by Epidarex Capital and Taiho Ventures to Advance Viral Cancer Therapies","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery Platform","country":"UNITED KINGDOM","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2021","url1":"","url2":"","graph1":"Large molecule","graph2":"Theolytics"},{"orgOrder":0,"company":"Enara Bio","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"D","amount":"$1,060.0 million","upfrontCash":"Undisclosed","newsHeadline":"Boehringer Ingelheim and Enara Bio Enter Strategic Collaboration to Discover Novel Shared Antigens for Cancer Immunotherapies","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery Platform","country":"UNITED KINGDOM","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"January 2021","url1":"","url2":"","graph1":"Undisclosed","graph2":"Enara Bio"},{"orgOrder":0,"company":"Artios Pharma Limited","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"D","amount":"$1,320.0 million","upfrontCash":"$20.0 million","newsHeadline":"Artios Pharma Announces Collaboration with Novartis to Create Next Generation DDR Cancer Therapies","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery Platform","country":"UNITED KINGDOM","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2021","url1":"","url2":"","graph1":"Large molecule","graph2":"Artios Pharma Limited"},{"orgOrder":0,"company":"Alchemab","sponsor":"AstraZeneca","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Alchemab to Collaborate with AstraZeneca on Prostate Cancer Research","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery Platform","country":"UNITED KINGDOM","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2021","url1":"","url2":"","graph1":"Large molecule","graph2":"Alchemab"},{"orgOrder":0,"company":"Exscientia","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"D","amount":"$1,375.0 million","upfrontCash":"$50.0 million","newsHeadline":"Exscientia Announces Multi-Target, AI-Driven Drug Discovery Collaboration with Bristol Myers Squibb","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery Platform","country":"UNITED KINGDOM","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"Exscientia"},{"orgOrder":0,"company":"Theolytics","sponsor":"M Ventures","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Theolytics Expands Series A Financing and Welcomes M Ventures as a New Investor","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery Platform","country":"UNITED KINGDOM","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2021","url1":"","url2":"","graph1":"Large molecule","graph2":"Theolytics"},{"orgOrder":0,"company":"Engitix Therapeutics","sponsor":"Dompe Farmaceutici","pharmaFlowCategory":"D","amount":"$54.0 million","upfrontCash":"Undisclosed","newsHeadline":"Engitix Announces $54m Series A Financing and a Strategic Collaboration with Domp\u00e9 Farmaceutici Using Exscalate\u2019s AI Supercomputing Power to Advance its Drug Discovery Pipeline in Fibrosis and Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery Platform","country":"UNITED KINGDOM","productType":"Large molecule","productStatus":"Undisclosed","date":"January 2022","url1":"","url2":"","graph1":"Large molecule","graph2":"Engitix Therapeutics"},{"orgOrder":0,"company":"LabGenius","sponsor":"Innovate UK","pharmaFlowCategory":"D","amount":"$1.2 million","upfrontCash":"Undisclosed","newsHeadline":"LabGenius Wins Government Innovation Grant to Support the Development of ML-driven Cancer Therapies","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery Platform","country":"UNITED KINGDOM","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2022","url1":"","url2":"","graph1":"Large molecule","graph2":"LabGenius"},{"orgOrder":0,"company":"Exscientia","sponsor":"Sanofi","pharmaFlowCategory":"D","amount":"$5,300.0 million","upfrontCash":"$100.0 million","newsHeadline":"Exscientia and Sanofi Establish Strategic Research Collaboration to Develop AI-driven Pipeline of Precision-engineered Medicines","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery Platform","country":"UNITED KINGDOM","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"Exscientia"},{"orgOrder":0,"company":"Curve Therapeutics","sponsor":"MSD Pharmaceuticals","pharmaFlowCategory":"D","amount":"$1,700.0 million","upfrontCash":"Undisclosed","newsHeadline":"Curve Therapeutics Announces Collaboration with MSD for Next Generation Drug Discovery Platform","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery Platform","country":"UNITED KINGDOM","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"Curve Therapeutics"},{"orgOrder":0,"company":"Antiverse","sponsor":"GlobalBio","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Antiverse and GlobalBio, Inc. Extend Collaboration to Advance Antibody Cancer Therapeutics","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery Platform","country":"UNITED KINGDOM","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2023","url1":"","url2":"","graph1":"Large molecule","graph2":"Antiverse"},{"orgOrder":0,"company":"T-Therapeutics","sponsor":"Sofinnova Partners","pharmaFlowCategory":"D","amount":"$60.0 million","upfrontCash":"Undisclosed","newsHeadline":"T-Therapeutics Raises \u00a348 Million Series A for Development of Next Generation TCR Therapeutics to Transform Cancer Treatment","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery Platform","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"November 2023","url1":"","url2":"","graph1":"Cell and Gene therapy","graph2":"T-Therapeutics"},{"orgOrder":0,"company":"Exscientia","sponsor":"Sanofi","pharmaFlowCategory":"D","amount":"$345.0 million","upfrontCash":"Undisclosed","newsHeadline":"Exscientia Announces Expansion of its Current Collaboration with Sanofi to Include Existing Exscientia Programme","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery Platform","country":"UNITED KINGDOM","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2023","url1":"","url2":"","graph1":"Small molecule","graph2":"Exscientia"},{"orgOrder":0,"company":"Enara Bio","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Boehringer Ingelheim Licenses Multiple Dark Antigens\u00ae from Enara Bio to Develop off-the-shelf Immunotherapies for Non-Small Cell Lung Cancer (NSCLC)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery Platform","country":"UNITED KINGDOM","productType":"Vaccine","productStatus":"New Molecular Entity","date":"January 2024","url1":"","url2":"","graph1":"Vaccine","graph2":"Enara Bio"},{"orgOrder":0,"company":"Vernalis","sponsor":"HOX Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Hox Therapeutics and Vernalis Announce a Drug Discovery Collaboration in Oncology","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery Platform","country":"UNITED KINGDOM","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2024","url1":"","url2":"","graph1":"Small molecule","graph2":"Vernalis"}]

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Loading...
Filters Filter
×
FILTER:
filter News Type
    filter Company
      filter Product Type
        filter Deal Size
          filter Upfront Payment

            Active Filter(s):

            Product Type

            Companies

            Details:

            Through collaboration, Vernalis will get access to the Hit ID platforms to produce the target protein, and to identify and characterise small molecule inhibitors of the oncology target.

            Lead Product(s): Undisclosed

            Therapeutic Area: Oncology Product Name: Undisclosed

            Highest Development Status: Discovery Platform Product Type: Small molecule

            Partner/Sponsor/Collaborator: HOX Therapeutics

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Collaboration February 20, 2024

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            Under the agreement, Boehringer exercised its option to license a number of cancer antigens discovered and validated using Enara Bio’s Dark Antigen discovery platform, EDAPT® and intends to develop novel off-the-shelf vaccines against non-small cell lung cancer (NSCLC).

            Lead Product(s): Undisclosed

            Therapeutic Area: Oncology Product Name: Undisclosed

            Highest Development Status: Discovery Platform Product Type: Vaccine

            Partner/Sponsor/Collaborator: Boehringer Ingelheim GmbH

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Collaboration January 04, 2024

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            Under the expanded collaboration, Sanofi is adding a new discovery stage programme identified and initially advanced by Exscientia, which has designed a novel lead series with data showing good potency and selectivity towards the target and differentiated molecular properties.

            Lead Product(s): Undisclosed

            Therapeutic Area: Oncology Product Name: Undisclosed

            Highest Development Status: Discovery Platform Product Type: Small molecule

            Partner/Sponsor/Collaborator: Sanofi

            Deal Size: $345.0 million Upfront Cash: Undisclosed

            Deal Type: Expanded Collaboration December 21, 2023

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            The company will use the net proceeds to discover and develop novel T cell receptor (TCR) therapeutics for cancer indications as well as inflammatory disorders.

            Lead Product(s): TCR Therapeutic

            Therapeutic Area: Oncology Product Name: Undisclosed

            Highest Development Status: Discovery Platform Product Type: Cell and Gene therapy

            Partner/Sponsor/Collaborator: Sofinnova Partners

            Deal Size: $60.0 million Upfront Cash: Undisclosed

            Deal Type: Series A Financing November 15, 2023

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            The extended collaboration aims to advance immune checkpoint inhibitors in cancer by leveraging Antiverse’s AI-driven antibody discovery platform. The initial collaboration resulted in the generation of anti-PD-1 antibodies, with 2 candidates entering preclinical development.

            Lead Product(s): Undisclosed

            Therapeutic Area: Oncology Product Name: Undisclosed

            Highest Development Status: Discovery Platform Product Type: Large molecule

            Partner/Sponsor/Collaborator: GlobalBio

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Collaboration October 16, 2023

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            LabGenius is pioneering the development of an ML-driven protein engineering platform. To date, EVA has co-optimised mono- and multi-specific single domain antibodies for biochemical and biofunctional properties, including stability, potency and selective tumour cell killing.

            Lead Product(s): Antibody-based Therapy

            Therapeutic Area: Oncology Product Name: Undisclosed

            Highest Development Status: Discovery Platform Product Type: Large molecule

            Partner/Sponsor/Collaborator: Innovate UK

            Deal Size: $1.2 million Upfront Cash: Undisclosed

            Deal Type: Funding November 30, 2022

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            Under the agreement with MSD, Curve will discover and validate novel small molecule modulators of up to five therapeutic targets using its Microcycle® technology, initially for oncology and neurology indications.

            Lead Product(s): Undisclosed

            Therapeutic Area: Oncology Product Name: Undisclosed

            Highest Development Status: Discovery Platform Product Type: Small molecule

            Partner/Sponsor/Collaborator: MSD Pharmaceuticals

            Deal Size: $1,700.0 million Upfront Cash: Undisclosed

            Deal Type: Collaboration February 16, 2022

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            The financing will be used to invest in Engitix’s internal drug discovery pipeline through IND-enabling studies, expand its ECM discovery platform and bioinformatics capabilities into new therapeutic areas, and to expand its team, facilities and operations.

            Lead Product(s): Undisclosed

            Therapeutic Area: Oncology Product Name: Undisclosed

            Highest Development Status: Discovery Platform Product Type: Large molecule

            Partner/Sponsor/Collaborator: Dompe Farmaceutici

            Deal Size: $54.0 million Upfront Cash: Undisclosed

            Deal Type: Series A Financing January 19, 2022

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            Under the term of agreement Sanofi is collaborating with Exscientia to develop up to 15 small molecules using Exscientia’s AI-driven platform for oncology and immunology targets.

            Lead Product(s): Undisclosed

            Therapeutic Area: Oncology Product Name: Undisclosed

            Highest Development Status: Discovery Platform Product Type: Small molecule

            Partner/Sponsor/Collaborator: Sanofi

            Deal Size: $5,300.0 million Upfront Cash: $100.0 million

            Deal Type: Collaboration January 07, 2022

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            The expanded Series A funding will support the progress of internal programmes in ovarian cancer, and a second cancer indication in addition to further advancing the company's unique technology platforms.

            Lead Product(s): Oncolytic Viral Therapies

            Therapeutic Area: Oncology Product Name: Undisclosed

            Highest Development Status: Discovery Platform Product Type: Large molecule

            Partner/Sponsor/Collaborator: M Ventures

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Series A Financing July 08, 2021

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity
            Post Enquiry
            POST ENQUIRY